Phio Pharma Surges After Releasing Pre-Clinical Data For PH-

Phio Pharmaceuticals Corp. (PHIO) shares are spiking more than 38 percent on Wednesday morning trade after the company presented key pre-clinical studies data for it Intasyl compound PH-894 aimed at melanoma cells, as an antitumor cytotoxic agent.

Related Keywords

Boston , Massachusetts , United States , , International Conference On Molecular , Phio Pharmaceuticals Corp , Phio Pharmaceuticals , Molecular Targets , Cancer Therapeutics , Stock Alert , Ohio , Phio Pharma ,